Quadrature Capital’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-6,837
Closed -$1.36M – 1457
2025
Q4
$1.36M Sell
6,837
-3,014
-31% -$547K 0.01% 451
2025
Q3
$1.54M Sell
9,851
-8,131
-45% -$1.29M 0.02% 334
2025
Q2
$2.73M Buy
+17,982
New +$2.4M 0.05% 248
2025
Q1
– Sell
-10,215
Closed -$1.88M – 1132
2024
Q4
$1.88M Buy
10,215
+6,745
+194% +$1.3M 0.04% 316
2024
Q3
$683K Sell
3,470
-41,941
-92% -$8.72M 0.02% 435
2024
Q2
$9.38M Buy
45,411
+38,960
+604% +$8.83M 0.16% 127
2024
Q1
$1.75M Buy
+6,451
New +$1.54M 0.03% 332
2022
Q4
– Sell
-48,638
Closed -$9.59M – 893
2022
Q3
$9.59M Buy
48,638
+1,924
+4% +$415K 0.31% 88
2022
Q2
$10M Buy
46,714
+36,024
+337% +$8.8M 0.42% 66
2022
Q1
$3.04M Buy
+10,690
New +$3.3M 0.12% 144
2021
Q1
– Sell
-900
Closed -$225K – 912
2020
Q4
$225K Buy
+900
New +$214K 0.01% 687
2020
Q3
– Sell
-3,700
Closed -$645K – 765
2020
Q2
$645K Buy
+3,700
New +$591K 0.07% 332
2017
Q2
– Sell
-8,553
Closed -$770K – 591
2017
Q1
$770K Sell
8,553
-15,723
-65% -$1.34M 0.06% 331
2016
Q4
$1.85M Buy
+24,276
New +$1.84M 0.06% 303

Other funds holding CRL

Quadrature Capital's CRL Position: Q1 2026 in Review

Quadrature Capital sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 6,837 shares — an estimated $1.36M sold.

Quadrature Capital first reported a position in CRL in Q4 2016 and held it in 14 quarters. The position peaked at $10M in Q2 2022. 560 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Quadrature Capital reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 6,837 Charles River Laboratories shares in Q1 2026, an estimated $1.36M.
  • Quadrature Capital first reported a position in Charles River Laboratories in Q4 2016 and held it in 14 quarters.
  • Quadrature Capital's Charles River Laboratories position peaked at $10M in Q2 2022.
  • 560 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.